Phase 1 dose-escalation study of anti CTLA-4 antibody ipilimumab and lenalidomide in patients with advanced cancers

Preclinical data suggest that combining a check point inhibition with immunomodulatory derivative can increase anticancer response. We designed a dose escalation study using a 3+3 design to determine the safety, maximum tolerated dose (MTD) or recommended phase 2 dose (R2PD) and dose limiting toxici...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Mol Cancer Ther
Main Authors: Sakamuri, Divya, Glitza, Isabella C., Betancourt Cuellar, Sonia L., Subbiah, Vivek, Fu, Siqing, Tsimberidou, Apostolia M., Wheler, Jennifer J., Hong, David S., Naing, Aung, Falchook, Gerald S., Fanale, Michelle A., Cabanillas, Maria E., Janku, Filip
Format: Artigo
Jezik:Inglês
Izdano: 2017
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5935561/
https://ncbi.nlm.nih.gov/pubmed/29237802
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-17-0673
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki